2fd6 › Citations

Structure of human urokinase plasminogen activator in complex with its receptor.

Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M
Science 311 656-9 (2006)
Cited: 200 times
EuropePMC logo PMID: 16456079

Abstract

The urokinase plasminogen activator binds to its cellular receptor with high affinity and initiates signaling cascades that are implicated in pathological processes including tumor growth, metastasis, and inflammation. We report the crystal structure at 1.9 angstroms of the urokinase receptor complexed with the urokinase amino-terminal fragment and an antibody against the receptor. The three domains of urokinase receptor form a concave shape with a central cone-shaped cavity where the urokinase fragment inserts. The structure provides insight into the flexibility of the urokinase receptor that enables its interaction with a wide variety of ligands and a basis for the design of urokinase-urokinase receptor antagonists.

Reviews - 2fd6 mentioned but not cited (4)

  1. Chemistry and Enzymology of Disulfide Cross-Linking in Proteins. Fass D, Thorpe C. Chem Rev 118 1169-1198 (2018)
  2. Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Goettig P. Int J Mol Sci 17 E1969 (2016)
  3. Endogenous phospholipase A2 inhibitors in snakes: a brief overview. Campos PC, de Melo LA, Dias GLF, Fortes-Dias CL. J Venom Anim Toxins Incl Trop Dis 22 37 (2016)
  4. The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities. Metrangolo V, Ploug M, Engelholm LH. Cancers (Basel) 13 5376 (2021)

Articles - 2fd6 mentioned but not cited (36)

  1. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. Kringelum JV, Lundegaard C, Lund O, Nielsen M. PLoS Comput Biol 8 e1002829 (2012)
  2. Benchmarking and analysis of protein docking performance in Rosetta v3.2. Chaudhury S, Berrondo M, Weitzner BD, Muthu P, Bergman H, Gray JJ. PLoS One 6 e22477 (2011)
  3. Protein-protein docking benchmark version 3.0. Hwang H, Pierce B, Mintseris J, Janin J, Weng Z. Proteins 73 705-709 (2008)
  4. Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. Sivasubramanian A, Sircar A, Chaudhury S, Gray JJ. Proteins 74 497-514 (2009)
  5. Application of asymmetric statistical potentials to antibody-protein docking. Brenke R, Hall DR, Chuang GY, Comeau SR, Bohnuud T, Beglov D, Schueler-Furman O, Vajda S, Kozakov D. Bioinformatics 28 2608-2614 (2012)
  6. SwarmDock and the use of normal modes in protein-protein docking. Moal IH, Bates PA. Int J Mol Sci 11 3623-3648 (2010)
  7. Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions? London N, Raveh B, Movshovitz-Attias D, Schueler-Furman O. Proteins 78 3140-3149 (2010)
  8. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. Lin L, Gårdsvoll H, Huai Q, Huang M, Ploug M. J Biol Chem 285 10982-10992 (2010)
  9. Search for allosteric disulfide bonds in NMR structures. Schmidt B, Hogg PJ. BMC Struct Biol 7 49 (2007)
  10. Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction. Gårdsvoll H, Jacobsen B, Kriegbaum MC, Behrendt N, Engelholm L, Østergaard S, Ploug M. J Biol Chem 286 33544-33556 (2011)
  11. Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Wang X, Singh SK, Kumar S. Pharm Res 27 1512-1529 (2010)
  12. Solution structure and phylogenetics of Prod1, a member of the three-finger protein superfamily implicated in salamander limb regeneration. Garza-Garcia A, Harris R, Esposito D, Gates PB, Driscoll PC. PLoS One 4 e7123 (2009)
  13. Prediction of protein-protein interaction sites using electrostatic desolvation profiles. Fiorucci S, Zacharias M. Biophys J 98 1921-1930 (2010)
  14. Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion. Khanna M, Wang F, Jo I, Knabe WE, Wilson SM, Li L, Bum-Erdene K, Li J, W Sledge G, Khanna R, Meroueh SO. ACS Chem Biol 6 1232-1243 (2011)
  15. A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR). Mertens HD, Kjaergaard M, Mysling S, Gårdsvoll H, Jørgensen TJ, Svergun DI, Ploug M. J Biol Chem 287 34304-34315 (2012)
  16. Encounter complexes and dimensionality reduction in protein-protein association. Kozakov D, Li K, Hall DR, Beglov D, Zheng J, Vakili P, Schueler-Furman O, Paschalidis ICh, Clore GM, Vajda S. Elife 3 e01370 (2014)
  17. Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. Gårdsvoll H, Kjaergaard M, Jacobsen B, Kriegbaum MC, Huang M, Ploug M. J Biol Chem 286 43515-43526 (2011)
  18. Epitope predictions indicate the presence of two distinct types of epitope-antibody-reactivities determined by epitope profiling of intravenous immunoglobulins. Luštrek M, Lorenz P, Kreutzer M, Qian Z, Steinbeck F, Wu D, Born N, Ziems B, Hecker M, Blank M, Shoenfeld Y, Cao Z, Glocker MO, Li Y, Fuellen G, Thiesen HJ. PLoS One 8 e78605 (2013)
  19. Protein-protein binding site identification by enumerating the configurations. Guo F, Li SC, Wang L, Zhu D. BMC Bioinformatics 13 158 (2012)
  20. Predicted structural mimicry of spike receptor-binding motifs from highly pathogenic human coronaviruses. Beaudoin CA, Jamasb AR, Alsulami AF, Copoiu L, van Tonder AJ, Hala S, Bannerman BP, Thomas SE, Vedithi SC, Torres PHM, Blundell TL. Comput Struct Biotechnol J 19 3938-3953 (2021)
  21. Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. Wang F, Li J, Sinn AL, Knabe WE, Khanna M, Jo I, Silver JM, Oh K, Li L, Sandusky GE, Sledge GW, Nakshatri H, Jones DR, Pollok KE, Meroueh SO. J Med Chem 54 7193-7205 (2011)
  22. Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction. Liu D, Xu D, Liu M, Knabe WE, Yuan C, Zhou D, Huang M, Meroueh SO. Biochemistry 56 1768-1784 (2017)
  23. Antigen recognition by antibody C836 through adjustment of V(L)/V(H) packing. Teplyakov A, Obmolova G, Malia T, Gilliland G. Acta Crystallogr Sect F Struct Biol Cryst Commun 67 1165-1167 (2011)
  24. Did evolution create a flexible ligand-binding cavity in the urokinase receptor through deletion of a plesiotypic disulfide bond? Leth JM, Mertens HDT, Leth-Espensen KZ, Jørgensen TJD, Ploug M. J Biol Chem 294 7403-7418 (2019)
  25. X-ray sequence and crystal structure of luffaculin 1, a novel type 1 ribosome-inactivating protein. Hou X, Chen M, Chen L, Meehan EJ, Xie J, Huang M. BMC Struct Biol 7 29 (2007)
  26. How to use not-always-reliable binding site information in protein-protein docking prediction. Li L, Huang Y, Xiao Y. PLoS One 8 e75936 (2013)
  27. A complete, multi-level conformational clustering of antibody complementarity-determining regions. Nikoloudis D, Pitts JE, Saldanha JW. PeerJ 2 e456 (2014)
  28. Cytotoxic Evaluation, Molecular Docking, and 2D-QSAR Studies of Dihydropyrimidinone Derivatives as Potential Anticancer Agents. Altaf R, Nadeem H, Ilyas U, Iqbal J, Paracha RZ, Zafar H, Paiva-Santos AC, Sulaiman M, Raza F. J Oncol 2022 7715689 (2022)
  29. PRISM-EM: template interface-based modelling of multi-protein complexes guided by cryo-electron microscopy density maps. Kuzu G, Keskin O, Nussinov R, Gursoy A. Acta Crystallogr D Struct Biol 72 1137-1148 (2016)
  30. Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography. Zhao B, Gandhi S, Yuan C, Luo Z, Li R, Gårdsvoll H, de Lorenzi V, Sidenius N, Huang M, Ploug M. Data Brief 5 107-113 (2015)
  31. Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain. Jiang Y, Lin L, Chen S, Jiang L, Kriegbaum MC, Gårdsvoll H, Hansen LV, Li J, Ploug M, Yuan C, Huang M. Int J Biol Sci 16 981-993 (2020)
  32. Protein-Protein Docking Using EMAP in CHARMM and Support Vector Machine: Application to Ab/Ag Complexes. Wright JD, Sargsyan K, Wu X, Brooks BR, Lim C. J Chem Theory Comput 9 4186-4194 (2013)
  33. Sampling the conformation of protein surface residues for flexible protein docking. Francis-Lyon P, Gu S, Hass J, Amenta N, Koehl P. BMC Bioinformatics 11 575 (2010)
  34. ALG3 Promotes Peritoneal Metastasis of Ovarian Cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8. Cui X, Pei X, Wang H, Feng P, Qin H, Liu S, Yan Q, Liu J. Cells 11 3141 (2022)
  35. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis. Abdellatif HAA, Sultan BO, Nassar HM, Gomaa MEE, Sakr MG, Riad E, Al-Harbi AI, Abdulhakim JA, Fawzy MS, Abd El-Fadeal NM. Int J Mol Sci 24 7177 (2023)
  36. PRISM-EM: template interface-based modelling of multi-protein complexes guided by cryo-electron microscopy density maps. Corrigendum. Kuzu G, Keskin O, Nussinov R, Gursoy A. Acta Crystallogr D Struct Biol 74 65-66 (2018)


Reviews citing this publication (47)

  1. Regulation of cell signalling by uPAR. Smith HW, Marshall CJ. Nat Rev Mol Cell Biol 11 23-36 (2010)
  2. Targeting nanoparticles to cancer. Wang M, Thanou M. Pharmacol Res 62 90-99 (2010)
  3. Proteases involved in cartilage matrix degradation in osteoarthritis. Troeberg L, Nagase H. Biochim Biophys Acta 1824 133-145 (2012)
  4. Evolving role of uPA/uPAR system in human cancers. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Cancer Treat Rev 34 122-136 (2008)
  5. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. Blasi F, Sidenius N. FEBS Lett 584 1923-1930 (2010)
  6. Pericellular proteolysis in cancer. Sevenich L, Joyce JA. Genes Dev 28 2331-2347 (2014)
  7. Role of urokinase receptor in tumor progression and development. Noh H, Hong S, Huang S. Theranostics 3 487-495 (2013)
  8. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Pillay V, Dass CR, Choong PF, Choong PF. Trends Biotechnol 25 33-39 (2007)
  9. Three-finger snake neurotoxins and Ly6 proteins targeting nicotinic acetylcholine receptors: pharmacological tools and endogenous modulators. Tsetlin VI. Trends Pharmacol Sci 36 109-123 (2015)
  10. Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance. Gettins PG, Olson ST. Biochem J 473 2273-2293 (2016)
  11. Therapeutics targeting the fibrinolytic system. Lin H, Xu L, Yu S, Hong W, Huang M, Xu P. Exp Mol Med 52 367-379 (2020)
  12. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Int J Infect Dis 11 289-299 (2007)
  13. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. O'Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP. Theranostics 3 496-506 (2013)
  14. Biophysical Mechanisms Mediating Fibrin Fiber Lysis. Hudson NE. Biomed Res Int 2017 2748340 (2017)
  15. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications. Li Santi A, Napolitano F, Montuori N, Ragno P. Int J Mol Sci 22 4111 (2021)
  16. Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials. Li R, Zheng K, Yuan C, Chen Z, Huang M. Nanotheranostics 1 346-357 (2017)
  17. Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements. Pulicherla KK, Verma MK. AAPS PharmSciTech 16 223-233 (2015)
  18. Profile of Matrix-Remodeling Proteinases in Osteoarthritis: Impact of Fibronectin. Pérez-García S, Carrión M, Gutiérrez-Cañas I, Villanueva-Romero R, Castro D, Martínez C, González-Álvaro I, Blanco FJ, Juarranz Y, Gomariz RP. Cells 9 E40 (2019)
  19. The neurobiological basis of sleep: Insights from Drosophila. Ly S, Pack AI, Naidoo N. Neurosci Biobehav Rev 87 67-86 (2018)
  20. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. Persson M, Kjaer A. Clin Physiol Funct Imaging 33 329-337 (2013)
  21. Lanthanide-doped luminescent nano-bioprobes for the detection of tumor markers. Chen Z, Zheng W, Huang P, Tu D, Zhou S, Huang M, Chen X. Nanoscale 7 4274-4290 (2015)
  22. Soluble urokinase receptor and focal segmental glomerulosclerosis. Reiser J, Wei C, Tumlin J. Curr Opin Nephrol Hypertens 21 428-432 (2012)
  23. Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist. Ploug M. Theranostics 3 467-476 (2013)
  24. Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus. Dande RR, Peev V, Altintas MM, Reiser J. J Diabetes Res 2017 3232848 (2017)
  25. Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor. Trimarchi H. World J Nephrol 2 103-110 (2013)
  26. Structural Biology and Protein Engineering of Thrombolytics. Mican J, Toul M, Bednar D, Damborsky J. Comput Struct Biotechnol J 17 917-938 (2019)
  27. Unwinding focal segmental glomerulosclerosis. Peev V, Hahm E, Reiser J. F1000Res 6 466 (2017)
  28. Effects of allopurinol on exercise-induced muscle damage: new therapeutic approaches? Sanchis-Gomar F, Pareja-Galeano H, Perez-Quilis C, Santos-Lozano A, Fiuza-Luces C, Garatachea N, Lippi G, Lucia A, Lucia A. Cell Stress Chaperones 20 3-13 (2015)
  29. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy. Nozaki S, Endo Y, Nakahara H, Yoshizawa K, Ohara T, Yamamoto E. Anticancer Drugs 17 1109-1117 (2006)
  30. Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer. Baart VM, Houvast RD, de Geus-Oei LF, Quax PHA, Kuppen PJK, Vahrmeijer AL, Sier CFM. EJNMMI Res 10 87 (2020)
  31. Proteases Revisited: Roles and Therapeutic Implications in Fibrosis. Kryczka J, Boncela J. Mediators Inflamm 2017 2570154 (2017)
  32. Type II transmembrane serine proteases as potential target for anti-influenza drug discovery. Shin WJ, Seong BL. Expert Opin Drug Discov 12 1139-1152 (2017)
  33. Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View. Alfano D, Franco P, Stoppelli MP. Front Cell Dev Biol 10 818616 (2022)
  34. Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer. Masucci MT, Minopoli M, Di Carluccio G, Motti ML, Carriero MV. Cancers (Basel) 14 498 (2022)
  35. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion. Nedaeinia R, Faraji H, Javanmard SH, Ferns GA, Ghayour-Mobarhan M, Goli M, Mashkani B, Nedaeinia M, Haghighi MHH, Ranjbar M. Mol Biol Rep 47 819-841 (2020)
  36. Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation. Gonias SL. Am J Physiol Cell Physiol 321 C721-C734 (2021)
  37. Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention. Leth JM, Ploug M. Front Cell Dev Biol 9 732015 (2021)
  38. Inflammation and Cardiovascular Disease Associated With Hemodialysis for End-Stage Renal Disease. Wang Y, Gao L. Front Pharmacol 13 800950 (2022)
  39. Mechanisms of Scarring in Focal Segmental Glomerulosclerosis. Zhong J, Whitman JB, Yang HC, Fogo AB. J Histochem Cytochem 67 623-632 (2019)
  40. uPAR: An Essential Factor for Tumor Development. Lv T, Zhao Y, Jiang X, Yuan H, Wang H, Cui X, Xu J, Zhao J, Wang J. J Cancer 12 7026-7040 (2021)
  41. Impact of expression of the uPA system in sarcomas. Taubert H, Magdolen V, Kotzsch M. Biomark Med 7 473-480 (2013)
  42. Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors. Xu P, Andreasen PA, Huang M. Int J Biol Sci 13 1222-1233 (2017)
  43. suPAR, a Circulating Kidney Disease Factor. Wei C, Spear R, Hahm E, Reiser J. Front Med (Lausanne) 8 745838 (2021)
  44. Biomarkers in AL Amyloidosis. Fotiou D, Theodorakakou F, Kastritis E. Int J Mol Sci 22 10916 (2021)
  45. The Perspective of Vitamin D on suPAR-Related AKI in COVID-19. Liao TH, Wu HC, Liao MT, Hu WC, Tsai KW, Lin CC, Lu KC. Int J Mol Sci 23 10725 (2022)
  46. Radiometallated peptides targeting guanylate cyclase C and the urokinase-type plasminogen activator receptor. Praharaj S, Overbey D, Giblin MF. Future Oncol 6 1325-1337 (2010)
  47. The Role of the Plasminogen/Plasmin System in Inflammation of the Oral Cavity. Yatsenko T, Skrypnyk M, Troyanovska O, Tobita M, Osada T, Takahashi S, Hattori K, Heissig B. Cells 12 445 (2023)

Articles citing this publication (113)

  1. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB. J Intern Med 268 296-308 (2010)
  2. Soluble Urokinase Receptor and Chronic Kidney Disease. Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. N Engl J Med 373 1916-1925 (2015)
  3. Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking. Chen F, Liu H, Sun H, Pan P, Li Y, Li D, Hou T. Phys Chem Chem Phys 18 22129-22139 (2016)
  4. uPAR-induced cell adhesion and migration: vitronectin provides the key. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. J Cell Biol 177 927-939 (2007)
  5. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. Chaurasia P, Aguirre-Ghiso JA, Liang OD, Gardsvoll H, Ploug M, Ossowski L. J Biol Chem 281 14852-14863 (2006)
  6. SLEEPLESS, a Ly-6/neurotoxin family member, regulates the levels, localization and activity of Shaker. Wu MN, Joiner WJ, Dean T, Yue Z, Smith CJ, Chen D, Hoshi T, Sehgal A, Koh K. Nat Neurosci 13 69-75 (2010)
  7. Soluble Urokinase Receptor and Acute Kidney Injury. Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, Sever S, Camacho A, Wang X, Dande RR, Ibrahim NE, Baron RM, Altintas MM, Wei C, Sheikh-Hamad D, Pan JS, Holliday MW, Januzzi JL, Weisbord SD, Quyyumi AA, Reiser J. N Engl J Med 382 416-426 (2020)
  8. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Huai Q, Zhou A, Lin L, Mazar AP, Parry GC, Callahan J, Shaw DE, Furie B, Furie BC, Huang M. Nat Struct Mol Biol 15 422-423 (2008)
  9. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Nielsen BS, Rank F, Illemann M, Lund LR, Danø K. Int J Cancer 120 2086-2095 (2007)
  10. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Lyngbæk S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, Linneberg A, Madsbad S, Haugaard SB, Eugen-Olsen J, Jeppesen J. Int J Cardiol 167 781-785 (2013)
  11. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. Gårdsvoll H, Ploug M. J Biol Chem 282 13561-13572 (2007)
  12. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J. J Mol Biol 363 482-495 (2006)
  13. Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. Royer-Zemmour B, Ponsole-Lenfant M, Gara H, Roll P, Lévêque C, Massacrier A, Ferracci G, Cillario J, Robaglia-Schlupp A, Vincentelli R, Cau P, Szepetowski P. Hum Mol Genet 17 3617-3630 (2008)
  14. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami ME, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS, International Study of Inflammation in COVID-19. J Am Soc Nephrol 31 2725-2735 (2020)
  15. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Connolly BM, Choi EY, Gårdsvoll H, Bey AL, Currie BM, Chavakis T, Liu S, Molinolo A, Ploug M, Leppla SH, Bugge TH. Blood 116 1593-1603 (2010)
  16. Lanthanide-doped luminescent nano-bioprobes: from fundamentals to biodetection. Liu Y, Tu D, Zhu H, Ma E, Chen X. Nanoscale 5 1369-1384 (2013)
  17. Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. Gårdsvoll H, Gilquin B, Le Du MH, Ménèz A, Jørgensen TJ, Ploug M. J Biol Chem 281 19260-19272 (2006)
  18. Conserved structural determinants in three-fingered protein domains. Galat A, Gross G, Drevet P, Sato A, Ménez A. FEBS J 275 3207-3225 (2008)
  19. Multifunctional Nano-Bioprobes Based on Rattle-Structured Upconverting Luminescent Nanoparticles. Lu S, Tu D, Hu P, Xu J, Li R, Wang M, Chen Z, Huang M, Chen X. Angew Chem Int Ed Engl 54 7915-7919 (2015)
  20. Sub-10 nm lanthanide-doped CaF2 nanoprobes for time-resolved luminescent biodetection. Zheng W, Zhou S, Chen Z, Hu P, Liu Y, Tu D, Zhu H, Li R, Huang M, Chen X. Angew Chem Int Ed Engl 52 6671-6676 (2013)
  21. Lanthanides: Applications in Cancer Diagnosis and Therapy. Teo RD, Termini J, Gray HB. J Med Chem 59 6012-6024 (2016)
  22. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Mölkänen T, Ruotsalainen E, Thorball CW, Järvinen A. Eur J Clin Microbiol Infect Dis 30 1417-1424 (2011)
  23. Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Greenberger S, Adini I, Boscolo E, Mulliken JB, Bischoff J. Angiogenesis 13 327-335 (2010)
  24. Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Kotzsch M, Sieuwerts AM, Grosser M, Meye A, Fuessel S, Meijer-van Gelder ME, Smid M, Schmitt M, Baretton G, Luther T, Magdolen V, Foekens JA. Breast Cancer Res Treat 111 229-240 (2008)
  25. Structural basis for EGFR ligand sequestration by Argos. Klein DE, Stayrook SE, Shi F, Narayan K, Lemmon MA. Nature 453 1271-1275 (2008)
  26. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Borné Y, Persson M, Melander O, Smith JG, Engström G. Eur J Heart Fail 16 377-383 (2014)
  27. A novel tumor targeting drug carrier for optical imaging and therapy. Li R, Zheng K, Hu P, Chen Z, Zhou S, Chen J, Yuan C, Chen S, Zheng W, Ma E, Zhang F, Xue J, Chen X, Huang M. Theranostics 4 642-659 (2014)
  28. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE. J Clin Gastroenterol 46 334-338 (2012)
  29. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. Zhao G, Yuan C, Wind T, Huang Z, Andreasen PA, Huang M. J Struct Biol 160 1-10 (2007)
  30. Multibiomarker analysis in patients with acute myocardial infarction. Schernthaner C, Lichtenauer M, Wernly B, Paar V, Pistulli R, Rohm I, Jung C, Figulla HR, Yilmaz A, Cadamuro J, Haschke-Becher E, Pernow J, Schulze PC, Hoppe UC, Kretzschmar D. Eur J Clin Invest 47 638-648 (2017)
  31. siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats. Zhang YP, Li WB, Wang WL, Liu J, Song SX, Bai LL, Hu YY, Yuan YD, Zhang M. Acta Pharmacol Sin 33 897-908 (2012)
  32. Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. Boonstra MC, Verbeek FP, Mazar AP, Prevoo HA, Kuppen PJ, van de Velde CJ, Vahrmeijer AL, Sier CF. BMC Cancer 14 269 (2014)
  33. Whole-genome sequencing analysis of the cardiometabolic proteome. Gilly A, Park YC, Png G, Barysenka A, Fischer I, Bjørnland T, Southam L, Suveges D, Neumeyer S, Rayner NW, Tsafantakis E, Karaleftheri M, Dedoussis G, Zeggini E. Nat Commun 11 6336 (2020)
  34. The urokinase plasminogen activator receptor promotes efferocytosis of apoptotic cells. D'mello V, Singh S, Wu Y, Birge RB. J Biol Chem 284 17030-17038 (2009)
  35. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. Hillig T, Engelholm LH, Ingvarsen S, Madsen DH, Gårdsvoll H, Larsen JK, Ploug M, Danø K, Kjøller L, Behrendt N. J Biol Chem 283 15217-15223 (2008)
  36. Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Mani T, Wang F, Knabe WE, Sinn AL, Khanna M, Jo I, Sandusky GE, Sledge GW, Jones DR, Khanna R, Pollok KE, Meroueh SO. Bioorg Med Chem 21 2145-2155 (2013)
  37. Origin and diversification of the plasminogen activation system among chordates. Chana-Muñoz A, Jendroszek A, Sønnichsen M, Wang T, Ploug M, Jensen JK, Andreasen PA, Bendixen C, Panitz F. BMC Evol Biol 19 27 (2019)
  38. Pneumococcal phosphoglycerate kinase interacts with plasminogen and its tissue activator. Fulde M, Bernardo-García N, Rohde M, Nachtigall N, Frank R, Preissner KT, Klett J, Morreale A, Chhatwal GS, Hermoso JA, Bergmann S. Thromb Haemost 111 401-416 (2014)
  39. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A, Dubrovskyi O, O'Halloran TV, Huang M, Mazar AP. PLoS One 9 e85349 (2014)
  40. Prediction of mortality in adult patients with sepsis using six biomarkers: a systematic review and meta-analysis. Pregernig A, Müller M, Held U, Beck-Schimmer B. Ann Intensive Care 9 125 (2019)
  41. The urokinase receptor homolog Haldisin is a novel differentiation marker of stratum granulosum in squamous epithelia. Gårdsvoll H, Kriegbaum MC, Hertz EP, Alpízar-Alpízar W, Ploug M. J Histochem Cytochem 61 802-813 (2013)
  42. Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study. Hayek SS, Ko YA, Awad M, Ahmed H, Gray B, Hosny KM, Aida H, Tracy MJ, Wei C, Sever S, Reiser J, Quyyumi AA. Kidney Int Rep 2 425-432 (2017)
  43. Letter Plasma levels of the active form of suPAR are associated with COVID-19 severity. Huang M, Li L, Shen J, Wang Y, Wang R, Yuan C, Huang M, Jiang L. Crit Care 24 704 (2020)
  44. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. Dupont DM, Madsen JB, Hartmann RK, Tavitian B, Ducongé F, Kjems J, Andreasen PA. RNA 16 2360-2369 (2010)
  45. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction. Liu D, Zhou D, Wang B, Knabe WE, Meroueh SO. ACS Chem Biol 10 1521-1534 (2015)
  46. An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope. Li Y, Parry G, Chen L, Callahan JA, Shaw DE, Meehan EJ, Mazar AP, Huang M. J Mol Biol 365 1117-1129 (2007)
  47. The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization. Liu Y, Cao DJ, Sainz IM, Guo YL, Colman RW. Am J Physiol Cell Physiol 295 C257-67 (2008)
  48. The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells. Ingangi V, Bifulco K, Yousif AM, Ragone C, Motti ML, Rea D, Minopoli M, Botti G, Scognamiglio G, Fazioli F, Gallo M, De Chiara A, Arra C, Grieco P, Carriero MV. Oncotarget 7 54474-54487 (2016)
  49. Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy. Chen Z, Xu P, Chen J, Chen H, Hu P, Chen X, Lin L, Huang Y, Zheng K, Zhou S, Li R, Chen S, Liu J, Xue J, Huang M. Acta Biomater 10 4257-4268 (2014)
  50. Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas. Carriero MV, Bifulco K, Ingangi V, Costantini S, Botti G, Ragone C, Minopoli M, Motti ML, Rea D, Scognamiglio G, Botti G, Arra C, Ciliberto G, Pessi A. Sci Rep 7 1312 (2017)
  51. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. Hayek SS, Landsittel DP, Wei C, Zeier M, Yu ASL, Torres VE, Roth S, Pao CS, Reiser J. J Am Soc Nephrol 30 1305-1313 (2019)
  52. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Liu D, Overbey D, Watkinson L, Giblin MF. Bioconjug Chem 20 888-894 (2009)
  53. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells. Ragone C, Minopoli M, Ingangi V, Botti G, Fratangelo F, Pessi A, Stoppelli MP, Ascierto PA, Ciliberto G, Motti ML, Carriero MV. J Exp Clin Cancer Res 36 180 (2017)
  54. Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence. Bifulco K, Votta G, Ingangi V, Di Carluccio G, Rea D, Losito S, Montuori N, Ragno P, Stoppelli MP, Arra C, Carriero MV. Oncotarget 5 4154-4169 (2014)
  55. Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis. Kriegbaum MC, Jacobsen B, Hald A, Ploug M. J Histochem Cytochem 59 188-201 (2011)
  56. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Sato S, Kopitz C, Grismayer B, Beaufort N, Reuning U, Schmitt M, Luther T, Kotzsch M, Krüger A, Magdolen V. Breast Cancer Res Treat 127 649-657 (2011)
  57. Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2. Larusch GA, Merkulova A, Mahdi F, Shariat-Madar Z, Sitrin RG, Cines DB, Schmaier AH. Am J Physiol Heart Circ Physiol 305 H305-20 (2013)
  58. Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release. Li S, Yuan C, Chen J, Chen D, Chen Z, Chen W, Yan S, Hu P, Xue J, Li R, Zheng K, Huang M. Theranostics 9 884-899 (2019)
  59. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry. Jacobsen B, Gårdsvoll H, Juhl Funch G, Ostergaard S, Barkholt V, Ploug M. Protein Expr Purif 52 286-296 (2007)
  60. Current advances in circulating inflammatory biomarkers in atherosclerosis and related cardio-cerebrovascular diseases. Lv JX, Kong Q, Ma X. Chronic Dis Transl Med 3 207-212 (2017)
  61. Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation. Vocca I, Franco P, Alfano D, Votta G, Carriero MV, Estrada Y, Caputi M, Netti PA, Ossowski L, Stoppelli MP. Int J Cancer 124 316-325 (2009)
  62. Orientation-controlled conjugation of haloalkane dehalogenase fused homing peptides to multifunctional nanoparticles for the specific recognition of cancer cells. Mazzucchelli S, Colombo M, Verderio P, Rozek E, Andreata F, Galbiati E, Tortora P, Corsi F, Prosperi D. Angew Chem Int Ed Engl 52 3121-3125 (2013)
  63. The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues. Gettins PG, Dolmer K. J Biol Chem 291 800-812 (2016)
  64. Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Jankun J, Aleem AM, Struniawski R, Lysiak-Szydłowska W, Selman SH, Skrzypczak-Jankun E. Pharmacol Rep 61 673-680 (2009)
  65. Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo. Zheng K, Li R, Zhou X, Hu P, Zhang Y, Huang Y, Chen Z, Huang M. Int J Nanomedicine 10 5327-5342 (2015)
  66. Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists. Xu D, Bum-Erdene K, Si Y, Zhou D, Ghozayel MK, Meroueh SO. ChemMedChem 12 1794-1809 (2017)
  67. Multi-biomarker analysis in patients after transcatheter aortic valve implantation (TAVI). Mirna M, Wernly B, Paar V, Jung C, Jirak P, Figulla HR, Kretzschmar D, Franz M, Hoppe UC, Lichtenauer M, Lauten A. Biomarkers 23 773-780 (2018)
  68. Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. Mirna M, Topf A, Wernly B, Rezar R, Paar V, Jung C, Salmhofer H, Kopp K, Hoppe UC, Schulze PC, Kretzschmar D, Schneider MP, Schultheiss UT, Sommerer C, Paul K, Wolf G, Lichtenauer M, Busch M. J Clin Med 9 E886 (2020)
  69. Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator. Zhao G, Yuan C, Bian C, Hou X, Shi X, Ye X, Huang Z, Huang M. Protein Expr Purif 49 71-77 (2006)
  70. A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces. Xu D, Si Y, Meroueh SO. J Chem Inf Model 57 2250-2272 (2017)
  71. A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts. Mazzieri R, Furlan F, D'Alessio S, Zonari E, Talotta F, Verde P, Blasi F. Oncogene 26 725-732 (2007)
  72. NMR solution structure of the neurotrypsin Kringle domain. Ozhogina OA, Grishaev A, Bominaar EL, Patthy L, Trexler M, Llinás M. Biochemistry 47 12290-12298 (2008)
  73. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity. Minopoli M, Polo A, Ragone C, Ingangi V, Ciliberto G, Pessi A, Sarno S, Budillon A, Costantini S, Carriero MV. Sci Rep 9 12169 (2019)
  74. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function. Nikorowitsch J, Borchardt T, Appelbaum S, Ojeda F, Lackner KJ, Schnabel RB, Blankenberg S, Zeller T, Karakas M. J Am Heart Assoc 9 e015452 (2020)
  75. Challenges for drug discovery - a case study of urokinase receptor inhibition. Chen Z, Lin L, Huai Q, Huang M. Comb Chem High Throughput Screen 12 961-967 (2009)
  76. Leach-proof magnetic thrombolytic nanoparticles and coatings of enhanced activity. Drozdov AS, Vinogradov VV, Dudanov IP, Vinogradov VV. Sci Rep 6 28119 (2016)
  77. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction. Sörensen NA, Nikorowitsch J, Neumann JT, Rübsamen N, Goßling A, Hartikainen TS, Blankenberg S, Westermann D, Zeller T, Karakas M. Clin Res Cardiol 108 1386-1393 (2019)
  78. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease. Mehta A, Desai SR, Ko YA, Liu C, Dhindsa DS, Nayak A, Hooda A, Martini MA, Ejaz K, Sperling LS, Reiser J, Hayek SS, Quyyumi AA. J Am Heart Assoc 9 e015457 (2020)
  79. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. Chen JS, Chang LC, Wu CZ, Tseng TL, Lin JA, Lin YF, Cheng CW. J Biomed Sci 23 24 (2016)
  80. Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years. Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Schutte AE. Hypertens Res 38 439-444 (2015)
  81. Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains. Bager R, Kristensen TK, Jensen JK, Szczur A, Christensen A, Andersen LM, Johansen JS, Larsen N, Baatrup E, Huang M, Ploug M, Andreasen PA. J Biol Chem 287 27526-27536 (2012)
  82. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies. Rasch MG, Pass J, Illemann M, Høyer-Hansen G, Lund IK. J Immunol Methods 339 55-65 (2008)
  83. Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles. Wang M, Miller AD, Thanou M. J Drug Target 21 684-692 (2013)
  84. Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures. Ge Y, Siegel AP, Jordan R, Naumann CA. Biophys J 107 2101-2111 (2014)
  85. Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients. Huang Y, Zhou H, Zhou H, Wu Y, Yang Y, Li W, Lu J, Hu Y. Dis Markers 2017 4719403 (2017)
  86. Soluble Urokinase Plasminogen Activator Receptor: A New Biomarker in the Pediatric Intensive Care Unit. El-Mekkawy MS, Saleh NY, Sonbol AA. Indian J Pediatr 83 661-669 (2016)
  87. A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance. Nieves EC, Manchanda N. J Biol Chem 285 12595-12603 (2010)
  88. A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging. Zhou X, Zheng K, Li R, Chen Z, Yuan C, Hu P, Chen J, Xue J, Huang M. Acta Biomater 23 116-126 (2015)
  89. Letter Crystal structure of the unoccupied murine urokinase-type plasminogen activator receptor (uPAR) reveals a tightly packed DII-DIII unit. Liu M, Lin L, Høyer-Hansen G, Ploug M, Li H, Jiang L, Yuan C, Li J, Huang M. FEBS Lett 593 1236-1247 (2019)
  90. Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Addition to High-Sensitivity Troponin I in Early Diagnosis of Acute Myocardial Infarction. Sörensen NA, Dönmez G, Neumann JT, Nikorowitsch J, Rübsamen N, Blankenberg S, Westermann D, Zeller T, Karakas M. Biomolecules 9 E108 (2019)
  91. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand. De Souza M, Matthews H, Lee JA, Ranson M, Kelso MJ. Bioorg Med Chem 19 2549-2556 (2011)
  92. Soluble Urokinase-Type Plasminogen Activator Receptor, Changes of 24-Hour Blood Pressure, and Progression of Chronic Kidney Disease. Jhee JH, Nam BY, Lee CJ, Park JT, Han SH, Kang SW, Park S, Yoo TH. J Am Heart Assoc 10 e017225 (2021)
  93. Acute effects of moderate altitude on biomarkers of cardiovascular inflammation and endothelial function and their differential modulation by dual endothelin receptor blockade. Lichtenauer M, Goebel B, Paar V, Wernly B, Gecks T, Rohm I, Förster M, Betge S, Figulla HR, Hoppe UC, Kelm M, Franz M, Jung C. Clin Hemorheol Microcirc 67 101-113 (2017)
  94. Computational Approaches and Analysis for a Spatio-Structural-Temporal Invasive Carcinoma Model. Hodgkinson A, Chaplain MAJ, Domschke P, Trucu D. Bull Math Biol 80 701-737 (2018)
  95. Computational identification of non-synonymous polymorphisms within regions corresponding to protein interaction sites. Skrlj B, Kunej T. Comput Biol Med 79 30-35 (2016)
  96. Crystal structure and cellular functions of uPAR dimer. Yu S, Sui Y, Wang J, Li Y, Li H, Cao Y, Chen L, Jiang L, Yuan C, Huang M. Nat Commun 13 1665 (2022)
  97. Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction. Bum-Erdene K, Liu D, Xu D, Ghozayel MK, Meroueh SO. ACS Med Chem Lett 12 60-66 (2021)
  98. Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections. Çitlenbik H, Ulusoy E, Er A, Çağlar A, Akgül F, Küme T, Yılmaz D, Duman M. Pediatr Allergy Immunol Pulmonol 32 121-127 (2019)
  99. Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit. Reisinger AC, Niedrist T, Posch F, Hatzl S, Hackl G, Prattes J, Schilcher G, Meißl AM, Raggam RB, Herrmann M, Eller P. Sci Rep 11 17476 (2021)
  100. The ovine urokinase plasminogen activator and its receptor cDNAs: molecular cloning, characterization and expression in various tissues. Theodorou G, Bizelis I, Rogdakis E, Politis I. Gene 443 158-169 (2009)
  101. Can soluble urokinase plasminogen receptor predict outcomes after cardiac surgery? Schultz-Swarthfigure CT, McCall P, Docking R, Galley HF, Shelley B. Interact Cardiovasc Thorac Surg 32 236-243 (2021)
  102. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis. Hindy G, Tyrrell DJ, Vasbinder A, Wei C, Presswalla F, Wang H, Blakely P, Ozel AB, Graham S, Holton GH, Dowsett J, Fahed AC, Amadi KM, Erne GK, Tekmulla A, Ismail A, Launius C, Sotoodehnia N, Pankow JS, Thørner LW, Erikstrup C, Pedersen OB, Banasik K, Brunak S, Ullum H, Eugen-Olsen J, Ostrowski SR, DBDS Consortium, Haas ME, Nielsen JB, Lotta LA, Regeneron Genetics Center, Engström G, Melander O, Orho-Melander M, Zhao L, Murthy VL, Pinsky DJ, Willer CJ, Heckbert SR, Reiser J, Goldstein DR, Desch KC, Hayek SS. J Clin Invest 132 e158788 (2022)
  103. Structural investigations of recombinant urokinase growth factor-like domain. Beloglazova IB, Beabealashvilli RSh, Gursky YG, Bocharov EV, Mineev KS, Parfenova EV, Tkachuk VA. Biochemistry (Mosc) 78 517-530 (2013)
  104. The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Context of Aneurysmal Subarachnoid Hemorrhage (aSAH)-A Prospective Observational Study. Schmidt TP, Albanna W, Weiss M, Veldeman M, Conzen C, Nikoubashman O, Blume C, Kluger DS, Clusmann H, Loosen SH, Schubert GA. Front Neurol 13 841024 (2022)
  105. Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy. Zheng K, Liu H, Liu X, Wang Y, Li L, Li S, Xue J, Huang M. Int J Nanomedicine 15 151-167 (2020)
  106. Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. Terpos E, Ntanasis-Stathopoulos I, Papassotiriou GP, Kastritis E, Margeli A, Kanellias N, Eleutherakis-Papaiakovou E, Migkou M, Fotiou D, Roussou M, Gavriatopoulou M, Malandrakis P, Psimenou E, Papassotiriou I, Dimopoulos MA. J Clin Med 9 E3201 (2020)
  107. DOT corrected fluorescence molecular tomography using targeted contrast agents for small animal tumor imaging. Tan Y, Cao Z, Sajja HK, Lipowska M, Wang YA, Yang L, Jiang H. J Xray Sci Technol 21 43-52 (2013)
  108. Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations. Wacker A, Bauder-Wüst U, Schäfer M, Schmidt J, Remde Y, Stadlbauer S, Eder M, Liolios C, Kopka K. J Labelled Comp Radiopharm 62 483-494 (2019)
  109. Identification of de novo EP300 and PLAU variants in a patient with Rubinstein-Taybi syndrome-related arterial vasculopathy and skeletal anomaly. Park JE, Kim E, Lee DW, Park TK, Kim MS, Jang SY, Ahn J, Park KB, Kim KH, Park HC, Ki CS, Kim DK. Sci Rep 11 15931 (2021)
  110. Soluble urokinase plasminogen activator receptor is associated with short-term mortality and enhanced reactive oxygen species production in acute-on-chronic liver failure. Wang Y, Wu F, Chen C, Xu L, Lin W, Huang C, Yang Y, Wu S, Qi J, Cao H, Li G, Hong M, Zhu H. BMC Gastroenterol 21 429 (2021)
  111. Targeted imaging of uPAR expression in vivo with cyclic AE105 variants. Leth JM, Newcombe EA, Grønnemose AL, Jørgensen JT, Qvist K, Clausen AS, Knudsen LBS, Kjaer A, Kragelund BB, Jørgensen TJD, Ploug M. Sci Rep 13 17248 (2023)
  112. The Protective Pathways Activated in Kidneys of αMUPA Transgenic Mice Following Ischemia\Reperfusion-Induced Acute Kidney Injury. Alkhaleq HA, Karram T, Fokra A, Hamoud S, Kabala A, Abassi Z. Cells 12 2497 (2023)
  113. The autoactivation of human single-chain urokinase-type plasminogen activator (uPA). Torres-Paris C, Chen Y, Xiao L, Song HJ, Chen P, Komives EA. J Biol Chem 299 105179 (2023)


Quick links